Stock analysis · Bull Rankings model

SRPT analysis

Sarepta Therapeutics, Inc.Biotechnology. Scored on the same transparent model behind the daily rankings.

Biotech & Gene Editing
SRPT
Sarepta Therapeutics, Inc. · Biotechnology
FCF$82mC-
Rev-36.2%F
D/E0.70C+
P/S1.3xA-
PEG
41.2Score
$17.18$1.8B
1Y Target$22.17Analyst consensus · 23 analysts
5Y Target$38.78Compound horizon
10Y Target$69.31Long-dated conviction
FCF$82mTTM
C-
FCF $82m — barely positive; fragile cash position
Rev-36.2%TTM YoY
F
Revenue -36.2% — severe decline
D/E0.70
C+
D/E 0.70 — above the Healthcare debt median (≈75th pctile)
P/S1.3x
A-
P/S 1.3x — cheaper than most Healthcare peers (≈25th pctile)
PEG
PEG not meaningful — earnings growth negative or data unavailable

Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.

Quality-growth score · 41.2
Quality0.23
Growth0.43
Value0.71
Why this score
  • Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week low
32% off the 12-month high
vs DCF fair value82% aboveest. fair value ~$9
What the price assumes: free cash flow compounding at ~13% a year for the next decade — vs the ~-5% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability43% · A-gross profit ÷ total assets (Novy-Marx)
ROIC-7.4% · Freturn on invested capital — not score-weighted

Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.

Why now
Biotechnology · market cap $1.8b. Down 32% from 52-week high of $25.32 — deep drawdown territory. Revenue -36% — in contraction; any catalyst that reverses this triggers re-rating. 23 sell-side analysts rate this a Hold with a mean 1-yr target of $22.17 (implying +29% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Revenue contracting -36% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -9.8%) — path to GAAP profitability is the core thesis risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $22.17 (23-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $38.78 — requires the platform / technology to reach commercial scale. 10 yr $69.31 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

SRPT vs the Top Picks average

PillarSRPTBook avgDiff
Quality0.230.83-0.60
Growth0.430.92-0.48
Value0.710.75-0.04

Averaged across the 30 names in today's Top Picks (mean score 82.4). A name can beat these averages and still be absent from the book — it also applies concentration limits.

Trend
+1.1 over 37 daily scores
From 40.1 (Jun 22) → 41.2 (now)

One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.

Shares to buy
116
Position size
$1,993
4.0% of portfolio
Stop price
$12.88
25% below $17.18
$ at risk if stopped
$498.22
budget $500.00 · 1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Sarepta Therapeutics, Inc. (SRPT): score, valuation & FAQ

Sarepta Therapeutics, Inc. (SRPT) is a Biotechnology company that scores 41.2 out of 100 on the Bull Rankings quality-growth model — a below-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.

Its strongest graded signals are P/S (A-), while FCF (C-) and Rev (F) rate weaker. On valuation, SRPT sits about 82% above our discounted-cash-flow fair value — the current price implies roughly 13% annual free-cash-flow growth over the next decade.

Is SRPT a good stock to buy?

Bull Rankings scores SRPT 41.2 out of 100 on its quality-growth model, which is a below-average reading. That is driven by P/S (A-). A score is a quantitative screen of Sarepta Therapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.

Why does SRPT score 41.2 on Bull Rankings?

The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). SRPT earns its highest marks on P/S (A-), and is held back by FCF (C-) and Rev (F). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.

Is SRPT overvalued or undervalued?

Based on $17.18, SRPT sits about 82% above our discounted-cash-flow fair value — the current price implies roughly 13% annual free-cash-flow growth over the next decade. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.

What are the main risks of investing in SRPT?

Revenue contracting -36% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -9.8%) — path to GAAP profitability is the core thesis risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.

New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.

Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.

More Biotechnology stocks by score

All Healthcare rankings →

Analyze another ticker →